Kiniksa Pharmaceuticals International plc Class A (KNSA)
NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 77.96 0.00%
KNSA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.08B
- P/E (TTM)
- 78.75
- Forward P/E
- 48.20
- EPS (TTM)
- $0.99
- Dividend yield
- None
- 52-week range
- 35.20 – 82.94
- Day range
- 74.70 – 79.22
- Volume / Avg
- 380.44K / 589.58K
- Beta
- —
- Shares outstanding
- 48.29M
- Next earnings
- Oct 27, 2026
52-week range
KNSA stock today
On Oct 7, KNSA ended the session at $77.96, adding $0.87 (1.13%), versus the S&P 500's 0.22% decline. Shares are 6.0% below their 52-week high of $82.94, set on Jul 29, 2026 and 121.5% above the 52-week low of $35.20, near the top of the past year's range. KNSA is up 88.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 104.1%.
At 78.7x trailing earnings, Kiniksa Pharmaceuticals International trades above the peer-group median of 30.9x. Its forward P/E of 48.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 27; analysts expect EPS of $0.39.
Summary generated from market data by MetaCap's automated system. Methodology
About Kiniksa Pharmaceuticals International
Company profileKiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Sanjiv K. Patel
- Headquarters
- London
- Employees
- 366
- IPO year
- 2018
- Website
- kiniksa.com
Financial highlights
Full financialsIn fiscal 2025, Kiniksa Pharmaceuticals International generated $677.6 million in revenue, up 60.1% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $59.0 million, for a net margin of 8.7% versus a median of -2.5% in the prior 5 years. Gross margin was 88.5% (up from 85.6%) and operating margin 11.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $677.56M | $423.24M | $270.26M | $220.18M | $38.54M |
| Growth | +60.09% | +56.60% | +22.74% | +471.24% | — |
| Net income | $59.01M | $-43.19M | $14.08M | $183.36M | $-157.92M |
| EPS (diluted) | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$98.00+25.71%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $0.39
- Last reported (Q1 2026)
- Apr 28, 2026
- EPS actual vs est.
- $0.27 vs —
KNSA news
All KNSA newsKiniksa Pharmaceuticals International peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RYTMRhythm Pharmaceuticals Inc. | 88.45 | -2.56% | $6.09B | vs KNSA |
| LGNDLigand Pharmaceuticals Incorporated | 293.26 | -1.24% | $5.85B | vs KNSA |
| BLTEBelite Bio Inc ADR | 156.08 | +0.30% | $6.29B | vs KNSA |
| PTCTPTC Therapeutics Inc. | 63.23 | -0.74% | $5.28B | vs KNSA |
| MIRMMirum Pharmaceuticals Inc. | 80.64 | +1.75% | $5.24B | vs KNSA |
| COGTCogent Biosciences Inc. | 30.14 | -0.79% | $5.23B | vs KNSA |
| AMRXAmneal Pharmaceuticals Inc. Class A | 19.65 | -3.18% | $6.84B | vs KNSA |
| GRFSGrifols S.A. ADR | 7.50 | -0.27% | $5.10B | vs KNSA |
Indexes, lists and sector
Kiniksa Pharmaceuticals International stock FAQ
What is Kiniksa Pharmaceuticals International's stock price today?
KNSA last traded at $77.96 as of Oct 7, 4:00 PM EDT, up 1.13% on the day. Prices are delayed at least 15 minutes.
When is Kiniksa Pharmaceuticals International's next earnings date?
Kiniksa Pharmaceuticals International is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $0.39.
What is KNSA's P/E ratio?
KNSA trades at a trailing P/E ratio of 78.75 and a forward P/E of 48.20, compared with a median of 30.9 for its closest peers.
Who is Kiniksa Pharmaceuticals International's CEO?
Mr. Sanjiv K. Patel is the chief executive officer of Kiniksa Pharmaceuticals International plc Class A, which has about 366 employees.
What is the KNSA 52-week high?
The 52-week high for KNSA is $82.94 and the 52-week low is $35.20. The stock is currently 6.0% below its high.